
Korean Biopharma Beefs Up Open Innovation to Raise Pipelines’ Value
The Korea Biomedical Review reported that Korean pharmaceutical and biotech companies are using various open innovation tools to raise competitiveness in new drug development in the global market. In the past, Korean drugmakers conducted research in secrecy due to the risk of technology leakage. But now, they actively get technologies and business
Comments Off on Korean Biopharma Beefs Up Open Innovation to Raise Pipelines’ Value • Read this story »
More Articles

Mark Samuels on Open Innovation in Pharma
The Pharma Times Online website posted an interview with Mark Samuels, chief business and strategy officer of the new Medicines Discovery Catapult, on the role of open innovation in big pharma: “I think collaborative research is increasingly important. Benefits of open innovation include access
Comments Off on Mark Samuels on Open Innovation in Pharma • Read this story »